Orwin John A — SEC Form 4 filings
SEC reporting owner CIK 1477384. 22 Form 4 filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2024-04-03 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 1 shares, $0 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 22,951 shares, $8,597 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 52.
- Largest priced transaction: sale of 22,951 shares @ $0.37 ($8,597) in Atreca, Inc., filed 2024-04-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Atreca, Inc. (BCEL) | PRESIDENT & CEO, Director | 2 | 1 leg · 1 sh · $0 | 1 leg · 22,951 sh · $8,597 | — |
| ANAPTYSBIO, INC (ANAB) | Director | 9 | — | — | 26 |
| First Tracks Biotherapeutics, Inc. (TRAX) | Director | 5 | — | — | 16 |
| Travere Therapeutics, Inc. (TVTX) | Director | 3 | — | — | 6 |
| CARGO Therapeutics, Inc. (CRGX) | Director | 3 | — | — | 4 |
Form 4 filings — Orwin John A
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 1,300 @ $0 · Option exercise (M): 1,300 (derivative) @ $0 | EDGAR |
| 2026-09-17 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Option exercise (M): 1,300 @ $0 · Option exercise (M): 1,300 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Option exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4/A | First Tracks Biotherapeutics, Inc. (TRAX) | Grant/award (A): 2,500 (derivative) @ $0 · Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | ANAPTYSBIO, INC (ANAB) | Disposition to issuer (D): 3,311 (derivative) @ $0 · Grant/award (A): 3,311 (derivative) @ $0 · Disposition to issuer (D): 10,600 (derivative) @ $0 · Grant/award (A): 10,600 (derivative) @ $0 · Disposition to issuer (D): 16,510 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · +4 more | EDGAR |
| 2026-04-22 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Grant/award (A): 3,311 (derivative) @ $0 · Grant/award (A): 10,600 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 8,250 (derivative) @ $0 · Grant/award (A): 1,300 (derivative) @ $0 · +2 more | EDGAR |
| 2026-01-08 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 8,250 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 1,300 @ $0 · Option exercise (M): 1,300 (derivative) @ $0 | EDGAR |
| 2025-08-19 | 4 | CARGO Therapeutics, Inc. (CRGX) | Disposition to issuer (D): 15,865 (derivative) · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2025-06-20 | 4 | CARGO Therapeutics, Inc. (CRGX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 6,030 (derivative) @ $0 | EDGAR |
| 2024-09-17 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 1,300 @ $0 · Option exercise (M): 1,300 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 2,035 @ $0 · Option exercise (M): 2,035 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | CARGO Therapeutics, Inc. (CRGX) | Grant/award (A): 23,742 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Atreca, Inc. (BCEL) | Purchase (P): 1 @ $0.01 | EDGAR |
| 2024-04-03 | 4 | Atreca, Inc. (BCEL) | Sale (S): 22,951 @ $0.37 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1477384 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →